Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$16.88-2.9%$12.49$4.64▼$20.77$206.86M2.84377,369 shs188,648 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%-12.63%+39.04%+82.29%+1.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$16.88-2.9%$12.49$4.64▼$20.77$206.86M2.84377,369 shs188,648 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%-12.63%+39.04%+82.29%+1.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 2.73Moderate Buy$45.86171.67% UpsideCurrent Analyst Ratings BreakdownLatest CRBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025CRBPCorbus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/20/2025CRBPCorbus PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$51.0010/20/2025CRBPCorbus PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingReduce10/20/2025CRBPCorbus PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$31.00 ➝ $38.0010/20/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.0010/8/2025CRBPCorbus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRBPCorbus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/17/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.008/6/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$56.00 ➝ $53.007/30/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$28.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%11/6/2025 (Estimated)Latest CRBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025CRBPCorbus Pharmaceuticals-$1.80N/AN/AN/AN/AN/A8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.55-$1.44+$0.11-$1.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A9.219.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4012.26 million11.81 millionOptionableCRBP HeadlinesRecent News About These CompaniesCorbus Pharmaceuticals' (CRBP) Sell (D-) Rating Reaffirmed at Weiss Ratings5 hours ago | marketbeat.comWilliam Blair Has Pessimistic Outlook of CRBP Q3 EarningsOctober 24 at 3:30 AM | americanbankingnews.comQ1 Earnings Estimate for CRBP Issued By WedbushOctober 24 at 2:41 AM | americanbankingnews.comWilliam Blair Issues Pessimistic Outlook for CRBP EarningsOctober 22, 2025 | marketbeat.comResearch Analysts Issue Forecasts for CRBP Q1 EarningsOctober 22, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Director Anne Altmeyer Sells 1,060 SharesOctober 22, 2025 | insidertrades.comHC Wainwright Reiterates "Buy" Rating for Corbus Pharmaceuticals (NASDAQ:CRBP)October 22, 2025 | americanbankingnews.comAnne Altmeyer Sells 1,060 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) StockOctober 21, 2025 | marketbeat.comWedbush Maintains Corbus Pharmaceuticals Holdings (CRBP) Outperform RecommendationOctober 21, 2025 | msn.comHC Wainwright & Co. Reiterates Corbus Pharmaceuticals Holdings (CRBP) Buy RecommendationOctober 21, 2025 | msn.comCorbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel TranscriptOctober 20, 2025 | seekingalpha.comCorbus stock surges after positive CRB-701 cancer treatment dataOctober 20, 2025 | au.investing.comCorbus Pharmaceuticals (NASDAQ:CRBP) Price Target Raised to $38.00 at WedbushOctober 20, 2025 | marketbeat.comCorbus Pharmaceuticals' (CRBP) Buy Rating Reiterated at HC WainwrightOctober 20, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from BrokeragesOctober 20, 2025 | americanbankingnews.comCorbus Pharmaceuticals presents CRB-701 clinical responses at ESMO25October 19, 2025 | msn.comAberdeen Group plc Buys 45,332 Shares of Corbus Pharmaceuticals Holdings, Inc. $CRBPOctober 19, 2025 | marketbeat.comCorbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25October 18, 2025 | globenewswire.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Rating of "Moderate Buy" from AnalystsOctober 15, 2025 | marketbeat.comCorbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025October 14, 2025 | markets.businessinsider.comCorbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology SymposiumOctober 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$16.88 -0.50 (-2.88%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$16.60 -0.28 (-1.66%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
